BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 23847277)

  • 1. Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation.
    Shabir S; Kaul B; Pachnio A; Banham GD; Smith H; Chand S; Jham S; Harper L; Ball S; Rahbar A; Söderberg-Nauclér C; Moss P; Borrows R
    J Am Soc Nephrol; 2013 Oct; 24(10):1698-708. PubMed ID: 23847277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMV-infected kidney grafts drive the expansion of blood-borne CMV-specific T cells restricted by shared class I HLA molecules via presentation on donor cells.
    Gatault P; Al-Hajj S; Noble J; Chevallier E; Piollet M; Forconi C; Gaudy-Graffin C; Thibault G; Miquelestorena-Standley E; Halimi JM; Büchler M; Lemoine R; Baron C
    Am J Transplant; 2018 Aug; 18(8):1904-1913. PubMed ID: 29377506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus-specific CD8+ T cells do not develop in all renal transplant patients at risk of virus infection.
    Christmas SE; Halliday D; Lawton N; Wang H; Abdalla I; Masters J; Hassan RL; Hart IJ; Khan N; Smith J; Hammad A; Bakran A
    Transpl Immunol; 2009 Dec; 22(1-2):99-104. PubMed ID: 19635559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
    Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
    Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary Cytomegalovirus Infection Significantly Impacts Circulating T Cells in Kidney Transplant Recipients.
    Meijers RW; Litjens NH; Hesselink DA; Langerak AW; Baan CC; Betjes MG
    Am J Transplant; 2015 Dec; 15(12):3143-56. PubMed ID: 26211927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients.
    Ugarte-Torres A; Hoegh-Petersen M; Liu Y; Zhou F; Williamson TS; Quinlan D; Sy S; Roa L; Khan F; Fonseca K; Russell JA; Storek J
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):574-85. PubMed ID: 20688181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant.
    López-Oliva MO; Martinez V; Buitrago A; Jiménez C; Rivas B; Escuin F; Santana MJ; Selgas R; Bellón T
    Transplantation; 2014 Apr; 97(8):839-45. PubMed ID: 24345896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients.
    Hughes D; Hafferty J; Fulton L; Friend P; Devaney A; Loke J; Welsh KI; Handa A; Klenerman P
    J Clin Virol; 2008 Feb; 41(2):92-5. PubMed ID: 18032098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective Assessment of Cytomegalovirus Immunity in High-Risk Donor-Seropositive/Recipient-Seronegative Liver Transplant Recipients Receiving Either Preemptive Therapy or Antiviral Prophylaxis.
    Limaye AP; Green ML; Edmison BC; Stevens-Ayers T; Chatterton-Kirchmeier S; Geballe AP; Singh N; Boeckh M
    J Infect Dis; 2019 Jul; 220(5):752-760. PubMed ID: 31112280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control.
    Popescu I; Pipeling MR; Shah PD; Orens JB; McDyer JF
    J Immunol; 2014 Dec; 193(11):5709-5722. PubMed ID: 25339676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Cytomegalovirus Serostatus on Allograft Loss and Mortality Within the First Year After Kidney Transplantation: An Analysis of the National Transplant Registry.
    Bruminhent J; Dajsakdipon T; Ingsathit A; Supaporn T; Prommool S; Watcharananan SP
    Transplant Proc; 2020 Apr; 52(3):829-835. PubMed ID: 32113693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation.
    Ganepola S; Gentilini C; Hilbers U; Lange T; Rieger K; Hofmann J; Maier M; Liebert UG; Niederwieser D; Engelmann E; Heilbronn R; Thiel E; Uharek L
    Bone Marrow Transplant; 2007 Mar; 39(5):293-9. PubMed ID: 17262060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients.
    Zhou W; Longmate J; Lacey SF; Palmer JM; Gallez-Hawkins G; Thao L; Spielberger R; Nakamura R; Forman SJ; Zaia JA; Diamond DJ
    Blood; 2009 Jun; 113(25):6465-76. PubMed ID: 19369230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection.
    Eid AJ; Brown RA; Arthurs SK; Lahr BD; Eckel-Passow JE; Larson TS; Razonable RR
    Transpl Int; 2010 May; 23(5):506-13. PubMed ID: 19951371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients.
    Egli A; Binet I; Binggeli S; Jäger C; Dumoulin A; Schaub S; Steiger J; Sester U; Sester M; Hirsch HH
    J Transl Med; 2008 Jun; 6():29. PubMed ID: 18541023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2018; 50(1):124-129. PubMed ID: 29407294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis.
    Leeaphorn N; Garg N; Thamcharoen N; Khankin EV; Cardarelli F; Pavlakis M
    Am J Transplant; 2019 Feb; 19(2):573-584. PubMed ID: 30431703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection.
    Gratama JW; van Esser JW; Lamers CH; Tournay C; Löwenberg B; Bolhuis RL; Cornelissen JJ
    Blood; 2001 Sep; 98(5):1358-64. PubMed ID: 11520783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection.
    Sester M; Sester U; Gärtner BC; Girndt M; Meyerhans A; Köhler H
    J Am Soc Nephrol; 2002 Oct; 13(10):2577-84. PubMed ID: 12239248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.